Matrix metalloproteinase inhibition as a novel anticancer strategy: A review with special focus on Batimastat and Marimastat

Pharmacology and Therapeutics

Volumn 75, Issue 1, 1997, Pages 69-75

  Rasmussen, Henrik S ^a   McCann, Peter P ^a  

^a British Biotech Inc   (United States)

Author keywords

Batimastat; Cancer; Marimastat; Matrix metalloproteinase inhibition; Metastasis

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER THERAPY; DRUG STRUCTURE; ENZYME INHIBITION; EXTRACELLULAR MATRIX; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; ENZYME INHIBITORS; FEMALE; HEMANGIOMA; HUMANS; HYDROXAMIC ACIDS; MELANOMA; METALLOENDOPEPTIDASES; MICE; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PHENYLALANINE; PROTEASE INHIBITORS; SKIN NEOPLASMS; THIOPHENES;

EID: 0030839472     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(97)00023-5     Document Type: Review

References (47)

1. Beattie, G. J., Young, H. A. and Smyth, J. F. (1994) Phase I study of intra-peritoneal metalloproteinase inhibitor BB-94 in patients with malignant ascites. In: Abstracts of the 8th NCI-EORTC Symposium on New Drug Development, Amsterdam, March 1994.
2. Beckett, R. P., Davidson, A. H., Drummond, A. H., Huxley, P. and Whittaker, M. (1996) Recent advances in matrix metalloproteinase inhibitor research. DDT 1: 16-26.
3. Boasberg, P., Harbaugh, B., Roth, B., Eisenberger, M., Langleben, A., Allen, R. and Rasmussen, H. (1996) Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. In: Proceedings of ASCO Thirty-Second Annual Meeting, May 18-21, Philadelphia, 15: 258.
4. Brown, P. D. and Giavazzi, R. (1995) Matrix metalloproteinase inhibition: a review of anti-tumor activity. Ann. Oncol. 6: 967-974.
5. Brown, P. D., Bloxodge, R. E., Stuart, N. S. A., Gatter, K. C. and Carmichael, J. (1993) Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small cell lung carcinoma. J. Natl. Cancer Inst. 85: 574-578.
6. Chirivi, R. G. S., Garofalo, A., Crimmin, M. J., Bawden, L. J., Stoppacciano, A., Brown, P. D. and Giavazzi, R. (1994) Inhibition of the metastatic spread and growth of B-16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor. Inj. J. Cancer 58: 460-464.
7. Cossins, J., Dudgeon, T. L., Catlin, G., Gearing, A. J. H. and Clements, J. M. (1996) Identification of MMP-18, a putative novel human matrix metalloproteinase. Biochem. Biophys. Res. Commun. 228: 494-498.
8. Davies, B., Brown, P., East., N., Crimmin, M. J. and Balkwill, F. R. (1993a) A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res. 53: 2087-2091. Erratum: Cancer Res. 53: 36521 (1993).
9. Davies, B., Miles, D. W., Happerfield, L. C., Naylor, M. S., Bobrow, L. G., Rubens, R. D. and Balkwill, F. R. (1993b) Activity of type IV collagenases in benign and malignant breast disease. Br. J. Cancer 67: 1126-1131.
10. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A. and Balkwill, F. (1993c) Levels of matrix metalloproteinases in bladder cancer correlate with tumor grade and invasion. Cancer Res. 53: 5365-5369.
11. Docherty, A. J. P., Lyons, A., Smith, B. J., Wright, E. M., Stephens, P. E. and Harris, T. J. R. (1985) Sequence of human tissue inhibitor of metalloproteinases and its identity to erythroid-potentiating activity. Nature 318: 66-69.
12. Drummond, A. H., Beckett, P., Bone, E. A., Brown, P. D., Davis, M., Galloway, W. A., Taupin, P., Wood, L. M. and Davidson, A. H. (1995) BB-2516: an orally bioavailable matrix metallo-proteinase inhibitor with efficacy in animal cancer models. Proc. Am. Assoc. Cancer Res. 36: 100.
13. Hamdy, F. C., Fadlon, D., Cottam, D., Lawry, J., Thurrell, W., Silcocks, P. B., Anderson, J. B., Williams, J. L. and Rees, R. C. (1994) Localization of messenger RNA for Mr 72,000 and 92,000 type IV collagenases in human skin cancers by in situ hybridization. Cancer Res. 52: 1336-1341.
14. Hart, I. R. (1979) The selection and characterization of an invasive variant of B16 melanoma. Am. J. Pathol. 97: 587-600.
15. Kleiner, D. E. and Stetler-Stevenson, W. G. (1993) Structural biochemistry and activation of matrix metalloproteinases. Curr. Opin. Cell Biol. 5: 891-897.
16. Kossakowska, A. E., Urbanski, S. J., Huchroft, S. A. and Edwards, D. R. (1992) Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncol. Res. 4: 233-240.
17. Kossakowska, A. E., Urbanski, S. J., Watson, A., Hayden, L. J. and Edwards, D. R. (1993) Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncol. Res. 5: 19-28.
18. Liotta, L. A. and Stetler-Stevenson, W. G. (1993) Principles of molecular cell biology of cancer: cancer metastasis. In: Cancer, Principles & Practice of Oncology, Vol. 1, 4th edn., pp. 134-149, DeVita, V. T., Hellman, S. and Rosenberg, S. A. (eds.) Lippincott Co., Philadelphia.
19. Macaulay, V. M., O'Byrne, K. J., Saunders, M. P., Salisbury, A., Long, L., Gleeson, F., Ganeson, T. S., Harris, A. L. and Talbot, D. C. (1995) Phase I study of the matrix metalloproteinase inhibitor batimastat (BB-94) in patients with malignant pleural effusion. Br. J. Cancer 71 (Suppl. 24): 11.
20. Malfetano, J., Teng, N., Moore, D., Barter, J., Lopez, A., Schink, J., Cole, A. and Rasmussen, H. S. (1996) Marimastat, a novel matrix metalloproteinase inhibitor in patients with advanced cancer of the ovary. A dose-finding study. In: Proceedings of ASCO Thirty-Second Annual Meeting, May 18-21, Philadelphia, 15: 283.
21. Matrisian, L. M. and Hogan, B. L. (1990) Growth factor-regulated proteases and extracellular matrix remodeling during mammalian development. Curr. Top. Dev. Biol. 24: 219-259.
22. Millar, A. and Brown, P. (1996) 360 Patient meta-analysis of studies of marimastat. A novel matrix metalloproteinase inhibitor. Ann. Oncol. 7 (Suppl. 5): 123.
23. Nuovo, G. J., MacConnell, P. B., Simsir, A., Valea, F. and French, D. L. (1995) Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNS and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 55: 267-275.
24. Parsons, S. L., Watson, S. A., Griffin, N. R. and Steele, R. J. C. (1996) An open phase I/II study of the oral matrix metalloproteinase inhibitor marimastat in patients with inoperable gastric cancer. Ann. Oncol. 7 (Suppl. 5): 47.
25. Poole, C., Adams, M., Barley, V., Graham, J., Helt, D., Louviaux, I., Perren, J., Piccait, M. and Thomas, H. (1996) A dose-finding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced ovarian cancer. Ann. Oncol. 7 (Suppl. 5): 68.
26. Primrose, J., Bleiberg, H., Daniel, F., Johnson, P., Mansi, J., Neoptolemos, J., Seymour, M. and Van Belle, S. (1996) A dosefinding study of marimastat, an oral matrix metalloproteinase inhibitor, in patients with advanced colorectal cancer. Ann. Oncol. 7 (Suppl. 5): 35.
27. Puente, X. S., Pendas, A. M., Llano, E., Velasco, G. and Lopez-Otin, C. (1996) Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 56: 944-949.
28. Rao, J. S., Steck, P. A. Mohanam, S., Stetler-Stevenson, W. G., Liotta, L. A. and Sawaya, R. (1993) Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res. 53: 2208-2211.
29. Rosemurgy, A., Harris, J., Langleben, A., Casper, E., Allen, R. and Rasmussen, H. S. (1996) Marimastat, a novel metalloproteinase inhibitor in patients with advanced carcinoma of the pancreas. In: Proceedings of ASCO Thirty-Second Annual Meeting, May 18-21, Philadelphia, 15: 207.
30. Rutka, J. T., Matsuzawa, K., Hubbard, S. L., Fukuyama, K., Becker, L., Stetler-Stevenson, W., Edwards, D. R. and Dicks, P. B. (1995) Expression of TIMP-1, TIMP-2, 72- and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: correlation with astrocytoma cell invasiveness. Int. J. Oncol. 6: 877-884.
31. Sato, H., Takino, T., Okada., M., Cao, J., Shingawa, A., Yamamoto, E., and Seiki, M. (1994) A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65.
32. Sledge, G. W., Jr., Qulali, M., Goulet, R., Bone, E. A. and Fife, R. (1995) Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. J. Natl. Cancer Inst. 87: 1546-1550.
33. Stetler-Stevenson, W. G., Krutzch, H. C. and Liotta, L. A. (1989) Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem. 264: 17374-17378.
34. Strongin, A., Collier, I., Bannikov, G., Marmer, B. L., Grant, G. A. and Goldberg, G. I. (1995) Mechanism of cell surface activation of 72 kDa type IV collagenase. J. Biol. Chem. 270: 5331-5338.
35. Sugarbaker, E. V. (1981) Patterns of metastasis in human malignancies. Cancer Biol. Rev. 2: 235.
36. Takino, T., Sato, H., Shinagawa, A. and Seiki, M. (1995) Identification of the second membrane-type matrix metalloproteinase (MT-MMP2) gene from a human placenta cDNA library. MT-MMPs form a unique membrane-type subclass in the MMP family. J. Biol. Chem. 270: 23013-23020.
37. Tamaki, M., McDonald, W. and DelMaestro, R. F. (1996) Release of collagen type IV degrading activity from C6 astrocytoma cells and cell density. J. Neurosurg. 84: 1013-1019.
38. Taraboletti, G., Garofalo, A., Belotti, D., Drudis, T., Borsothi, P., Scanziani, E., Brown, P. D. and Giavazzi, R. (1995) Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. J. Natl. Cancer Inst. 87: 293-298.
39. Urbanski, S. J., Edwards, D. R., Maitland, A., Leco, K. J., Watson, A. and Kossakowska, A. E. (1992) Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. Br. J. Cancer 66: 1188-1194.
40. Urbanski, S. J., Edwards, D. R., Hershfield, N., Huchcroft, S. A., Shaffer, E., Sutherland, L. and Kossakowska, A. E. (1993) Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagn. Mol. Pathol. 2: 81-89.
41. Wang, X., Fu, X., Brown, P. D., Crimmin, M. J. and Hoffman, R. M. (1994) Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res. 54: 4726-4728.
42. Weiss, L. and Gilbert, H. A. (1981) Bone Metastasis. G. K. Hall, Boston.
43. Will, H. and Hinzman, B. (1995) cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur. J. Biochem. 231: 602-608.
44. Woessner, J. F., Jr. (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J. 5: 2145-2154.
45. Wojtowicz-Praga, S., Low, J., Marshall, J., Ness, E., Dickson, R., Barter, J., Sale, M., McCann, P., Moore, J., Cole, A. and Hawkins, M. (1996) Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer. Invest. New Drugs 14: 193-202.
46. Zeng, Z. S. and Guillem, J. G. (1995) Distinct pattern of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 mRNA expression in human colorectal cancer and liver metastases. Br. J. Cancer 72: 575-582.
47. Zeng, Z. S., Huang, Y., Cohen, A. M. and Guillem, J. G. (1996) Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase 9. J. Clin. Oncol. 14: 3133-3140.